Table 1.
Demographics, Patient Characteristics, and Visit Timing (n = 81)
| Mean (SD) | |
|---|---|
| Age (years) | 58.5 (11.0) |
| Education (years) | 13.7 (2.3) |
| N (%) | |
| Male | 62 (76.5) |
| Female | 19 (23.5) |
| Race | |
| Caucasian/White | 77 (95.1) |
| Black or African American | 4 (4.9) |
| Marital Status | |
| Married | 59 (72.8) |
| Single | 11 (13.6) |
| Single, living with partner | 4 (4.9) |
| Widowed | 4 (4.9) |
| Other | 3 (3.7) |
| History of smokinga | 57 (70.4) |
| History of alcohol useb | 49 (60.5) |
| Clinical characteristics of sample, N = 81, n (%) | |
| HN cancer location | |
| Oropharynx | 38 (46.9) |
| Oral cavity | 19 (23.5) |
| Larynx | 12 (14.8) |
| Salivary gland | 4 (4.9) |
| Nasopharynx | 3 (3.7) |
| Hypopharynx | 2 (2.5) |
| Paranasal sinuses | 2 (2.5) |
| Other | 1 (1.2) |
| Squamous cell carcinoma | 71 (87.7) |
| HPV+ | 26 (32.1) |
| Stage | |
| I | 1 (1.2) |
| II | 3 (3.7) |
| III | 18 (22.2) |
| Iva | 54 (66.7) |
| Ivb | 5 (6.2) |
| Surgery | 36 (44.4) |
| Tracheotomy (at any time) | 18 (22.2) |
| PEG tube (at any time) | 44 (54.3) |
| Total treatment received N = 79, n (%) | |
| ChemoXRT | 12 (15.2) |
| Induction and chemoXRT | 36 (45.6) |
| Surgery and chemoXRT | 22 (27.8) |
| Surgery and radiotherapy | 2 (2.5) |
| Induction, surgery, and chemoXRT | 7 (8.9) |
| Median [IQR] | |
| Months since HNC diagnosis | 1.0 [0–2] |
| Months since surgery (n = 36) | 1.1 [−1 to 2] |
| Total radiation dose (cGy) | 6930 [6255–11370] |
| Cycles of induction chemotherapy (n = 45) | 7.0 [3–8] |
| No. of concurrent chemoradiation treatments (N = 77) | 6.0 [5–7] |
| Closest study visit to swallow study date | N (%) |
| Baseline | 13 (16.0) |
| End of treatment | 13 (16.0) |
| 6 Weeks | 16 (19.8) |
| 12 Weeks | 5 (6.2) |
| 18 Weeks | 5 (6.2) |
| 24 Weeks | 1 (1.2) |
| 30 Weeks | 1 (1.2) |
| 36 Weeks | 1 (1.2) |
| 42 Weeks | 3 (3.7) |
| 15 Months | 3 (3.7) |
| 18 Months | 20 (24.7) |
a
N = 55.
b
N = 44.
HNC, head and neck cancer; IQR, interquartile range; SD, standard deviation.